Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, exceeding prior estimates.
Latest Ratings for GILD
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | Barclays | Maintains | Underweight | |
| Mar 2022 | RBC Capital | Maintains | Outperform | |
| Feb 2022 | BMO Capital | Downgrades | Outperform | Market Perform |
